These Cholesterol-Reducers May Save Lives. So Why Aren ’ t Heart Patients Getting Them?
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices.
Source: NYT Health - Category: Consumer Health News Authors: GINA KOLATA Tags: Repatha (Drug) Drugs (Pharmaceuticals) Health Insurance and Managed Care Cholesterol Prices (Fares, Fees and Rates) Heart Amgen Inc CIGNA Corporation Express Scripts Inc Regeneron Pharmaceuticals Inc Source Type: news
More News: Cardiology | Cholesterol | Health | Health Insurance | Heart | Insurance | Insurers | Managed Care